abrdn Life Sciences Investors (NYSE:HQL) Reaches New 12-Month High – Should You Buy?

Shares of abrdn Life Sciences Investors (NYSE:HQL) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $21.42 and last traded at $21.3610, with a volume of 23881 shares trading hands. The stock had previously closed at $21.24.

abrdn Life Sciences Investors Price Performance

The stock’s 50-day moving average is $19.36 and its 200 day moving average is $17.89.

abrdn Life Sciences Investors Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Monday, August 24th will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 11.7%. The ex-dividend date is Monday, August 24th.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Hedge funds have recently modified their holdings of the business. KPP Advisory Services LLC grew its position in shares of abrdn Life Sciences Investors by 2.7% in the 2nd quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock valued at $505,000 after purchasing an additional 660 shares during the period. Geneos Wealth Management Inc. raised its holdings in abrdn Life Sciences Investors by 200.1% during the 2nd quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after buying an additional 1,529 shares during the period. NewEdge Advisors LLC lifted its stake in abrdn Life Sciences Investors by 5.2% in the second quarter. NewEdge Advisors LLC now owns 34,190 shares of the company’s stock valued at $438,000 after buying an additional 1,690 shares in the last quarter. Uhlmann Price Securities LLC lifted its stake in abrdn Life Sciences Investors by 2.3% in the first quarter. Uhlmann Price Securities LLC now owns 77,857 shares of the company’s stock valued at $1,267,000 after buying an additional 1,719 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in shares of abrdn Life Sciences Investors by 4.0% in the fourth quarter. First Trust Advisors LP now owns 48,770 shares of the company’s stock valued at $818,000 after buying an additional 1,880 shares during the period. Institutional investors and hedge funds own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.